ArriVent BioPharma (AVBP) Accumulated Expenses (2023 - 2026)
ArriVent BioPharma (AVBP) posted Accumulated Expenses of $16.2 million for Q1 2026, down 19.14% sequentially from $20.0 million in Q4 2025, and up 943.83% YoY from $1.5 million in Q1 2025.
ArriVent BioPharma (AVBP) Accumulated Expenses (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Accumulated Expenses for 4 years, with the latest figure at $16.2 million in Q1 2026.
- Quarterly Accumulated Expenses rose 943.83% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (up 943.83% YoY) and the FY2025 annual result came in at $20.0 million, up 380.35% from the prior year.
- Accumulated Expenses eased to $16.2 million in Q1 2026 per AVBP's latest filing, from $20.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $20.0 million in Q4 2025 and troughed at $1.5 million in Q1 2025.
- A 4-year average of $8.6 million and a median of $6.3 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses sank 72.98% in 2025, then soared 943.83% in 2026.
- Over 4 years, Accumulated Expenses stood at $3.4 million in 2023, then advanced by 24.16% to $4.2 million in 2024, then surged by 380.35% to $20.0 million in 2025, then fell by 19.14% to $16.2 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $16.2 million, $20.0 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.31 Mn |
| Mar 31, 2026 | 16.17 Mn |
| Dec 31, 2025 | 20.00 Mn |
| Sep 30, 2025 | 10.82 Mn |
| Jun 30, 2025 | 15.48 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | 6.84 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 5.73 Mn |
| Dec 31, 2023 | 3.35 Mn |